Drugs / red cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05638581 | Jul 2023 → Dec 2026 expected | — | University of Alabama at Birmingham | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | red cells | “Participants will receive separated blood components (i.e., units of red cells, plasma, platelets, and cryoprecipitate) co-administered intravenously or intraosseously.” NCT05638581 ↗ |
| Known as | red blood cells | “Balanced transfusion with red blood cells, plasma, and platelets (component therapy, CT) has been shown to reduce mortality” PMID 40753420 ↗ Aug 2025 |
| Route | Intravenous | “co-administered intravenously or intraosseously” NCT05638581 ↗ |
| Route | Other | “co-administered intravenously or intraosseously” NCT05638581 ↗ |